Coherus Oncology, Inc. Cash and Restricted Cash
Coherus Oncology, Inc. (CHRS) had Cash and Restricted Cash of $83.16 million as of 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Cash Flow › Cash
us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents · last filed 2026-08-05
- 2026-06-30: Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $83.16M.
- 2026-03-31: Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $115.48M.
- 2025-12-31: Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $89.12M.
- 2025-09-30: Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $103.59M.
| Period end | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents |
|---|---|
| 2026-06-30 | $83.16M 10-Q · filed 2026-08-05 |
| 2026-03-31 | $115.48M 10-Q · filed 2026-05-11 |
| 2025-12-31 | $89.12M 10-Q · filed 2026-08-05 |
| 2025-09-30 | $103.59M 10-Q · filed 2025-11-06 |
| 2025-06-30 | $217.16M 10-Q · filed 2026-08-05 |
| 2025-03-31 | $82.67M 10-Q · filed 2026-05-11 |
| 2024-12-31 | $126.25M 10-Q · filed 2026-08-05 |
| 2024-09-30 | $97.95M 10-Q · filed 2025-11-06 |
| 2024-06-30 | $159.69M 10-Q · filed 2025-08-07 |
| 2024-03-31 | $260.23M 10-Q · filed 2025-05-12 |
| 2023-12-31 | $103.34M 10-K · filed 2026-03-09 |
| 2023-09-30 | $80.71M 10-Q · filed 2024-11-06 |
| 2023-06-30 | $73.36M 10-Q · filed 2024-08-08 |
| 2023-03-31 | $16.59M 10-Q · filed 2024-05-09 |
| 2022-12-31 | $63.99M 8-K · filed 2025-11-13 |
| 2022-09-30 | $287.25M 10-Q · filed 2023-11-06 |
| 2022-06-30 | $275.92M 10-Q · filed 2023-08-02 |
| 2022-03-31 | $326.12M 10-Q · filed 2023-05-08 |
| 2021-12-31 | $417.63M 10-K · filed 2025-03-17 |
| 2021-09-30 | $360.98M 10-Q · filed 2022-11-08 |
| 2021-06-30 | $330.18M 10-Q · filed 2022-08-04 |
| 2021-03-31 | $259.93M 10-Q · filed 2022-05-05 |
| 2020-12-31 | $541.60M 10-K · filed 2024-03-15 |
| 2020-09-30 | $292.90M 10-Q · filed 2021-11-08 |
| 2020-06-30 | $225.06M 10-Q · filed 2021-08-05 |
| 2020-03-31 | $193.69M 10-Q · filed 2021-05-06 |
| 2019-12-31 | $177.91M 10-K · filed 2023-03-06 |
| 2019-09-30 | $165.17M 10-Q · filed 2020-11-05 |
| 2019-06-30 | $106.76M 10-Q · filed 2020-08-06 |
| 2019-03-31 | $82.35M 10-Q · filed 2020-05-07 |
| 2018-12-31 | $73.19M 10-K · filed 2022-02-23 |
| 2018-09-30 | $102.04M 10-Q · filed 2019-11-08 |
| 2018-06-30 | $130.84M 10-Q · filed 2019-08-05 |
| 2018-03-31 | $82.86M 10-Q · filed 2019-05-09 |
| 2017-12-31 | $127.76M 10-K · filed 2021-02-25 |
| 2017-09-30 | $136.40M 10-Q · filed 2018-11-08 |
| 2017-06-30 | $74.20M 10-Q · filed 2018-08-08 |
| 2017-03-31 | $125.77M 10-Q · filed 2018-05-10 |
| 2016-12-31 | $125.79M 10-K · filed 2019-02-28 |
| 2015-12-31 | $159.07M 10-K · filed 2019-02-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Alpha Cognition Inc. (ACOG) | $0.185B | -6.77 | |
| PRECISION BIOSCIENCES INC (DTIL) | United States | $0.175B | -3.95 |
| Voyager Therapeutics, Inc. (VYGR) | United States | $0.173B | -1.99 |
| Protara Therapeutics, Inc. (TARA) | United States | $0.198B | -3.22 |
| Acumen Pharmaceuticals, Inc. (ABOS) | United States | $0.162B | -1.83 |
| Outlook Therapeutics, Inc. (OTLK) | United States | $0.162B | -4.90 |
| Compass Therapeutics, Inc. (CMPX) | United States | $0.204B | -5.35 |
| Humacyte, Inc. (HUMA) | United States | $0.155B | -2.26 |
| Alector, Inc. (ALEC) | United States | $0.213B | -1.90 |
| ANAVEX LIFE SCIENCES CORP. (AVXL) | United States | $0.218B | -18.37 |